These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

123 related items for PubMed ID: 3995220

  • 1. Resin-coated 5-aminosalicylic acid (Asacol) in rheumatoid arthritis.
    Situnayake RD, McConkey B.
    Br J Rheumatol; 1985 May; 24(2):226-7. PubMed ID: 3995220
    [No Abstract] [Full Text] [Related]

  • 2. Experience with Eudragit-S coated mesalamine (Asacol) in inflammatory bowel disease: adverse events.
    Nichols TW.
    J Clin Gastroenterol; 1994 Mar; 18(2):181. PubMed ID: 8189029
    [No Abstract] [Full Text] [Related]

  • 3. Is Asacol as effective as sulphasalazine in maintaining remission of Crohn's disease and ulcerative colitis?
    Nakshabendi IM, Duncan A, Russell RI.
    Postgrad Med J; 1992 Mar; 68(797):189-91. PubMed ID: 1350343
    [Abstract] [Full Text] [Related]

  • 4. Experience with Eudragit-S-coated mesalamine (Asacol) in inflammatory bowel disease. An open study.
    Faber SM, Korelitz BI.
    J Clin Gastroenterol; 1993 Oct; 17(3):213-8. PubMed ID: 8228082
    [Abstract] [Full Text] [Related]

  • 5. [Effect of 5-aminosalicylic acid as a constituent of sulfasalazine in the treatment of chronic polyarthritis].
    Wörth WD, Müller W.
    Z Rheumatol; 1986 Oct; 45(2):79-82. PubMed ID: 2873695
    [Abstract] [Full Text] [Related]

  • 6. Which component of sulphasalazine is active in rheumatoid arthritis?
    Pullar T, Hunter JA, Capell HA.
    Br Med J (Clin Res Ed); 1985 May 25; 290(6481):1535-8. PubMed ID: 2860942
    [Abstract] [Full Text] [Related]

  • 7. 5-Aminosalicylic acid or sulphapyridine. Which is the active moiety of sulphasalazine in rheumatoid arthritis?
    Taggart AJ, Neumann VC, Hill J, Astbury C, Le Gallez P, Dixon JS.
    Drugs; 1986 May 25; 32 Suppl 1():27-34. PubMed ID: 2877851
    [Abstract] [Full Text] [Related]

  • 8. Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study.
    Sninsky CA, Cort DH, Shanahan F, Powers BJ, Sessions JT, Pruitt RE, Jacobs WH, Lo SK, Targan SR, Cerda JJ.
    Ann Intern Med; 1991 Sep 01; 115(5):350-5. PubMed ID: 1863024
    [Abstract] [Full Text] [Related]

  • 9. [Aminosalicylates in chronic inflammatory intestinal diseases and rheumatoid arthritis].
    Maier KP.
    Dtsch Med Wochenschr; 1992 Oct 16; 117(42):1614-5. PubMed ID: 1356747
    [No Abstract] [Full Text] [Related]

  • 10. The value of 5-aminosalicylic acid in inflammatory bowel disease for patients intolerant or allergic to sulphasalazine.
    Donald IP, Wilkinson SP.
    Postgrad Med J; 1985 Dec 16; 61(722):1047-8. PubMed ID: 2869480
    [Abstract] [Full Text] [Related]

  • 11. [The treatment of inflammatory intestinal diseases with preparations of 5-aminosalicylic acid].
    Frol'kis AV.
    Ter Arkh; 1996 Dec 16; 68(2):75-7. PubMed ID: 8771669
    [No Abstract] [Full Text] [Related]

  • 12. Evaluation of an enteric-coated delayed-release 5-aminosalicylic acid tablet in patients with inflammatory bowel disease.
    Hardy JG, Healey JN, Reynolds JR.
    Aliment Pharmacol Ther; 1987 Aug 16; 1(4):273-80. PubMed ID: 2979672
    [Abstract] [Full Text] [Related]

  • 13. Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers.
    Sandborn WJ, Hanauer SB, Buch A.
    Aliment Pharmacol Ther; 2004 May 15; 19(10):1089-98. PubMed ID: 15142198
    [Abstract] [Full Text] [Related]

  • 14. Maintenance of remission in ulcerative colitis with oral preparation of 5-aminosalicylic acid.
    Dew MJ, Hughes P, Harries AD, Williams G, Evans BK, Rhodes J.
    Br Med J (Clin Res Ed); 1982 Oct 09; 285(6347):1012. PubMed ID: 6127137
    [No Abstract] [Full Text] [Related]

  • 15. Bioavailability of single and multiple doses of enteric-coated mesalamine and sulphasalazine.
    Corey AE, Rose GM, Conklin JD.
    J Int Med Res; 1990 Oct 09; 18(6):441-53. PubMed ID: 1981363
    [Abstract] [Full Text] [Related]

  • 16. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.
    Rachmilewitz D.
    BMJ; 1989 Jan 14; 298(6666):82-6. PubMed ID: 2563951
    [Abstract] [Full Text] [Related]

  • 17. Gastrointestinal transit of an enteric-coated delayed-release 5-aminosalicylic acid tablet.
    Hardy JG, Healey JN, Lee SW, Reynolds JR.
    Aliment Pharmacol Ther; 1987 Jun 14; 1(3):209-16. PubMed ID: 2979223
    [Abstract] [Full Text] [Related]

  • 18. A study to determine the active moiety of sulphasalazine in rheumatoid arthritis.
    Neumann VC, Taggart AJ, Le Gallez P, Astbury C, Hill J, Bird HA.
    J Rheumatol; 1986 Apr 14; 13(2):285-7. PubMed ID: 2873245
    [Abstract] [Full Text] [Related]

  • 19. [Mesalazine].
    Engelhardt K, Mohr K.
    Dtsch Med Wochenschr; 1995 May 26; 120(21):769-70. PubMed ID: 7781502
    [No Abstract] [Full Text] [Related]

  • 20. Uncoated versus coated 5-aminosalicylic acid in Crohn's disease.
    Bossi A, Giuliani GE, Del Poggio P, Fenili D, Ragaini S.
    Lancet; 1989 Feb 04; 1(8632):276. PubMed ID: 2563434
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.